TrialPloS one2013

A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.

Siying Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.